Dr Llewellyn Mills

South Eastern Sydney Local Health District

NSW

19th May 2021

Dear Dr Llewellyn Mills,

**RE: NCR4SF18:**

**Examining the effects of Amphetamine-Type-Substance use on clinical outcomes among clients receiving opioid agonist treatment**

Thank you for your application to The National Centre for Clinical Research on Emerging Drugs (NCCRED) 4th round of grant funding (February 2021). We appreciate the time and effort you took in applying for this grant.

Your grant application was reviewed by the NCCRED Clinical Research Network Methamphetamine and Emerging Drugs Working Group on 11 May 2021. This was an independent process, in which the NCCRED staff and Board of Directors were not involved.

As chair of the WG, I am pleased to inform you that your application for an NCCRED value-add grant was successful. The WG tabled their recommendations to the NCCRED Board on 17th May 2021 and funding was approved. The grant awarded is $42,536.78.


You will shortly receive four copies of a contract signed by UNSW as NCCRED’s funding administrator. This will need to be approved and executed by your institution prior to the release of any funds, with two wet-ink signed copies returned to NCCRED and one wet-ink copy retained by your institution. Any amendments or changes to the contract/terms and conditions requested by your institution can be negotiated through the NCCRED staff.

Please reply to this letter by email to Jemma Hallen (jemma.hallen@unsw.edu.au) indicating:

1. You are willing to be included on the NCCRED website as a recipient of an NCCRED grant
2. You are willing for your project synopsis to be included on the NCCRED website and promoted through their reports or newsletters
3. You are willing to mention NCCRED as the source of funding for any publications or promotional activity related to the project

If you have any questions or require additional information, please contact me.

Sincerely,



Associate Professor Robert Ali

Chair NCCRED Clinical Research Network

Methamphetamine and Emerging Drugs Working Group

T: +61 (0)8 83138057

M: +61 (0) 401 124 516

E: robert.ali@adelaide.edu.au

Cc: Members of the WG, Nadine Ezard (Director, NCCRED), Krista Siefried (Clinical Research Lead, NCCRED)